論文

2021年9月22日

Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan.

Japanese journal of infectious diseases
  • Mugen Ujiie
  • ,
  • Shinya Tsuzuki
  • ,
  • Michiyo Suzuki
  • ,
  • Masayuki Ota
  • ,
  • Tetsuya Suzuki
  • ,
  • Hidetoshi Nomoto
  • ,
  • Kei Yamamoto
  • ,
  • Sho Saito
  • ,
  • Akatsuki Kokaze
  • ,
  • Noriko Kinoshita

74
5
開始ページ
399
終了ページ
404
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.7883/yoken.JJID.2020.947

Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine is generally used for booster vaccination in Europe and the United States to avoid increased reactogenicity after diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccination in infants. However, Japan has extended the use of additional DTaP vaccination without reducing the antigen dose for diphtheria and pertussis to adolescents and adults despite limited reports on its safety in adults. This prospective observational questionnaire-based study investigated the occurrence of adverse events (AEs) following DTaP vaccination between June 2018 and June 2019 in participants aged 10 years or older. Of 250 eligible participants, 235 (94%) responded regarding AEs. Of these 235 participants, 133 (56.6%) reported AEs, with 39 reporting systemic AEs (16.6%) and 120 reporting local AEs (51.1%) attributed to DTaP vaccination. The incidence of local AEs was much higher with DTaP than with non-DTaP vaccinations (51.1% vs. 10.2%), and the AEs appeared later (p<0.01) and lasted longer (p<0.01) with DTaP vaccination. However, more than 75% of these AEs resolved within 7 days. DTaP vaccination was not associated with any serious AEs. These results indicate that the DTaP vaccine can be widely used as a booster in adults as an alternative to the Tdap vaccine.

リンク情報
DOI
https://doi.org/10.7883/yoken.JJID.2020.947
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33518629
ID情報
  • DOI : 10.7883/yoken.JJID.2020.947
  • PubMed ID : 33518629

エクスポート
BibTeX RIS